TSRX Key Stats
- Cubist, Optimer, Trius: Antibiotic Deal Making On Tap May 22
- Nasdaq stocks posting largest percentage increases May 20
- Trius Patent Intrigues Investors, And Perhaps Cubist Pharmaceuticals May 16
- 7 Biotechnology Stocks to Sell Now Investor Place May 15
- Stocks Hitting 52-Week Highs Benzinga May 15
- Trius Therapeutics: New, Positive Dimension For Investment Outlook May 13
- Trius Therapeutics (TSRX) Tedizolid Phosphate Portfolio Receives NoA from UPTO Street Insider May 13
- Trius Announces Notice of Allowance of U.S. Patent Application Related to Tedizo... May 13
- Alimera Sciences And Trius Therapeutics: 2 Big Biotechs For 2013 May 13
- Guggenheim Starts Trius Therapeutics (TSRX) at Buy Street Insider May 10
TSRX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Trius Therapeutics is up 57.94% over the last year vs S&P 500 Total Return up 27.96%, Genomic Health up 11.42%, and Acorda Therapeutics up 44.35%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for TSRX
Pro Report PDF for TSRX
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download TSRX Pro Report PDF
Pro Strategies Featuring TSRX
Did Trius Therapeutics make it into our Pro Portfolio Strategies?